ARTICLE
15 April 2014

Healthcare & Life Sciences Private Equity Deal Tracker: Adaptive Biotechnologies Secures $105 Million In Financing

Adaptive Biotechnologies has announced it has completed a series C financing round and completed a newly created series D round of financing.
United States Food, Drugs, Healthcare, Life Sciences

Adaptive Biotechnologies has announced it has completed a series C financing round and completed a newly created series D round of financing with a $105 million investment from Viking Global Investors.

Adaptive Biotechnologies, based in Seattle, Wash., is an immunosequencing diagnostics company with a focus in oncology.

Viking Global Investors, based in Greenwich, Conn., is a global investment firm managing more than $20 billion in capital across long-short equity and long-only strategies.

The new funding for Adaptive Biotechnologies will be initially allocated to the expansion of the company's immunoSEQ research platform through the launch of a research use only kit in the third quarter of 2014.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More